BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Welireg (Belzutifan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Welireg (Belzutifan)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06234605-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Welireg (Belzutifan): Phase 1 readout est. (NCT06234605)
DESCRIPTION:Welireg (Belzutifan)\, phase 1\, Renal Cell Carcinoma.\nStudy: 
 A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients
  With Renal Cell Carcinoma\nEstimated primary completion: November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06234605
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468697-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Welireg (Belzutifan): Phase 1/2 readout est. (NCT05468697)
DESCRIPTION:Welireg (Belzutifan)\, phase 1/2\, Renal Cell Carcinoma.\nStudy
 : A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus B
 elzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (
 MK-6482-024/LITESPARK-024)\nEstimated primary completion: 22 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05468697
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03634540-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT03634540)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 A Trial of Belzutifan (PT2977\, MK-6482) in Combination With Cabozantinib 
 in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)\nEs
 timated primary completion: 26 February 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03634540
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04976634-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT04976634)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: Pembrolizumab Plus Lenv
 atinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)\nEstim
 ated primary completion: 22 March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04976634
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680205-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07680205)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: An Experimental Study o
 f Belzutifan Impact on Catecholamine Metabolism\nEstimated primary complet
 ion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belz
 utifan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07680205
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03401788-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT03401788)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 A Phase 2 Study of Belzutifan (PT2977\, MK-6482) for the Treatment of Von 
 Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482
 -004)\nEstimated primary completion: 29 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03401788
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428396-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT06428396)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: Study of Belzutifan (MK
 -6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-02
 9/LITESPARK-029)\nEstimated primary completion: 5 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06428396
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030506-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Welireg (Belzutifan): Phase 1 readout est. (NCT05030506)
DESCRIPTION:Welireg (Belzutifan)\, phase 1\, Renal Cell Carcinoma.\nStudy: 
 A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Len
 vatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China P
 articipants With Advanced Renal Cell Carcinoma (MK-6482-010)\nEstimated pr
 imary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/belzutifan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05030506
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187778-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270719
DTEND;VALUE=DATE:20270720
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07187778)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combinat
 ion as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)\nEst
 imated primary completion: 19 July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07187778
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Welireg (Belzutifan): Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Welireg (Belzutifan)\, phase 1/2.\nStudy: Study of Pembrolizuma
 b (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prost
 ate Cancer (MK-3475-365/KEYNOTE-365)\nEstimated primary completion: 22 Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT028
 61573
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06677190-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT06677190)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: Belzutifan in Recurrent
  Clear Cell Carcinoma of Gynecologic Origin\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 lzutifan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06677190
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07907341-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Welireg (Belzutifan): Phase 4 readout est. (NCT07907341)
DESCRIPTION:Welireg (Belzutifan)\, phase 4.\nStudy: Safety and Efficacy of 
 Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/
 Paraganglioma (PPGL)\nEstimated primary completion: 31 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07907341
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07593040-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07593040)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Rena
 l Cell Carcinoma\nEstimated primary completion: January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07593040
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023432-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07023432)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmeta
 static Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)\nEstimated primary com
 pletion: 14 April 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/belzutifan#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07023432
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793942-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280926
DTEND;VALUE=DATE:20280927
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07793942)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: A Clinical Trial of MK-
 2010 Alone and With Other Treatments in Participants With Advanced Solid T
 umors (MK-2010-002)\nEstimated primary completion: 26 September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07793942
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895966-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07895966)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: Phase IIA Study of Belz
 utifan in EPAS1-\, EGLN1-\, or VHL-Mutant Erythrocytosis\nEstimated primar
 y completion: 30 September 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/belzutifan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07895966
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840001-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07840001)
DESCRIPTION:Welireg (Belzutifan)\, phase 2\, Renal Cell Carcinoma.\nStudy: 
 Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk\, Locally Advanced 
 Clear Cell Renal Cell Carcinoma\nEstimated primary completion: April 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07840001
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049926-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20311026
DTEND;VALUE=DATE:20311027
SUMMARY:Welireg (Belzutifan): Phase 1/2 readout est. (NCT07049926)
DESCRIPTION:Welireg (Belzutifan)\, phase 1/2\, Renal Cell Carcinoma.\nStudy
 : Substudy 03C: A Study of Combination Therapies in Participants With Rena
 l Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Thera
 py (MK-3475-03C/KEYMAKER-U03)\nEstimated primary completion: 26 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/belzutifan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07049926
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227402-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20320227
DTEND;VALUE=DATE:20320228
SUMMARY:Welireg (Belzutifan): Phase 3 readout est. (NCT07227402)
DESCRIPTION:Welireg (Belzutifan)\, phase 3\, Renal Cell Carcinoma.\nStudy: 
 A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent 
 Kidney Cancer Following Adjuvant Therapy (MK-6482-033)\nEstimated primary 
 completion: 27 February 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/belzutifan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07227402
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04924075-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20321118
DTEND;VALUE=DATE:20321119
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT04924075)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: Belzutifan/MK-6482 for 
 the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)\, Pancreat
 ic Neuroendocrine Tumor (pNET)\, Von Hippel-Lindau (VHL) Disease-Associate
 d Tumors\, Advanced Gastrointestinal Stromal Tumor (wt GIST)\, or Solid Tu
 mors With HIF-2α Related Genetic Alterations (MK-6482-015)\nEstimated pri
 mary completion: 18 November 2032. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/belzutifan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04924075
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700758-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20340102
DTEND;VALUE=DATE:20340103
SUMMARY:Welireg (Belzutifan): Phase 2 readout est. (NCT07700758)
DESCRIPTION:Welireg (Belzutifan)\, phase 2.\nStudy: A Study of Belzutifan i
 n Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)\nE
 stimated primary completion: 2 January 2034. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07700758
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405164-11244@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20340422
DTEND;VALUE=DATE:20340423
SUMMARY:Welireg (Belzutifan): Phase 3 readout est. (NCT07405164)
DESCRIPTION:Welireg (Belzutifan)\, phase 3.\nStudy: Extension Study for Par
 ticipants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)\n
 Estimated primary completion: 22 April 2034. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/belzutifan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07405164
URL:https://assetmemo.bio/drug/belzutifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
